ArticlePDF Available

'You never told me I would turn into a gambler': A first person account of dopamine agonist - Induced gambling addiction in a patient with restless legs syndrome

Authors:

Abstract

Dopaminergic agents are commonly used and effective treatments for restless legs syndrome (RLS), a disabling sensorimotor disorder. Less known are some of the potentially disabling side effects of these treatments, particularly iatrogenic gambling addiction, as is described here. Here the authors present a 62-year-old man, with a 20-year history of RLS, who developed gambling addiction while on dopaminergic treatment. He was not forewarned of this side effect, nor was he ever screened for gambling behaviours prior to or during treatment. Eight months after discontinuation of dopaminergic treatment and after 10 sessions of cognitive-behavioural therapy for gambling addiction, his gambling behaviours have partially resolved. To our knowledge, this is the first ever first person account of this condition. To prevent the devastating consequences of gambling addiction or to minimise its impact by early intervention, the authors call for clinicians involved in treatment of RLS to follow these simple measures: screen patients for gambling behaviours prior to the onset and during dopaminergic treatment; forewarn patients of this potential side effect; and if patients screen positive, refer them to specialist gambling treatment services, in addition to making necessary changes to their medication regime.
BMJ Case Reports 2011; doi:10.1136/bcr.07.2011.4459 1 of 3
BACKGROUND
Introduction
Restless legs syndrome (RLS) can often be a very disabling
sensorimotor disorder. Although there are no UK-based
prevalence studies, international studies have found rates
of between 3% and 10%.
1 The four essential diagnostic cri-
teria for RLS are: urge to move, onset or exacerbation with
rest, relief with movement and night time onset or wors-
ening of symptoms.
2 Although the precise pathophysi-
ological mechanisms underlying RLS have not been clearly
elucidated, some point to dopaminergic depletion, thereby
implicating the nigrostriatal dopaminergic loop.
3 Given
this etiological explanation, it follows that dopaminergic
drugs such as levadopa/carbedopa, ropinirole, pramipexole
and pergolide can be useful treatments in alleviating the
symptoms of RLS. Although not very common, impulse
control disorders (such as gambling addiction, which is the
focus of this case report) are potentially devastating side
effects of dopaminergic treatment.
4
6 Gambling addiction
and other impulse control disorders have previously been
reported as a common side effect of dopaminergic treat-
ment for Parkinson’s disease
7
8 – a disorder sharing sev-
eral commonalities with RLS, in its underlying aetiology,
characteristics and treatment. However, iatrogenic gam-
bling addiction as a result of dopaminergic treatment for
RLS has been less studied, although some case reports and
prevalence surveys have emerged recently (see discussion
section); and clinicians and patients are not adequately
aware of this.
Hence this side effect (iatrogenic gambling addiction),
during the course of treatment for RLS, often goes unrecog-
nised and unaddressed, leading to even more detrimental
consequences for the affected individual and family. What
motivated us to share this patient’s story was his comment
to one of the authors, ‘they should have forewarned me
that this medication could turn me into a gambler. Then
things would not have got as bad as they did, and cer-
tainly I would not have blamed myself’. Through this case
description, we hope to raise clinicians’ awareness of this
iatrogenic condition and we call for more regular screen-
ing for gambling behaviours prior to and during treatment
with dopaminergic agents.
CASE PRESENTATION
Given below is the patients own account of his gambling
addiction, a direct consequence of dopaminergic treatment
for his RLS.
‘I am a 62-year-old retired school teacher, and this is
my story of how I turned into a gambler, or to be more
precise, how I was turned into a gambler. I had restless
legs ever since I can remember; started very early in child-
hood I think. My father had it too. About 20 years ago, it
became more of a concern, so I went and saw my general
practitioner. He referred me to a neurologist for special-
ist treatment. The neurologist started me on dopaminer-
gic medications (sinemet and cabergoline). I have been on
some medication or the other since. Medications make my
condition better and I sleep better. Apart from this, my life
was okay until I retired about 2 years ago. I had never gam-
bled, except for a fl utter, once a year – a pound or so, on
the Grand National; nothing more, ever.
So, I had been on these medications (sinemet and caber-
goline, then cabergoline was switched to ropinirole, later
changed to rotigotine) for over 18 years and I was doing
Reminder of important clinical lesson
You never told me I would turn into a gambler’: a fi rst person
account of dopamine agonist – induced gambling addiction in
a patient with restless legs syndrome
Henrietta Bowden Jones, 1 Sanju George 2
1 Department of Neurosciences and Mental Health, Imperial College, London, UK ;
2 Department of Addiction Psychiatry, Birmingham and Solihull Mental Health NHS Trust, Birmingham, UK
Correspondence to Dr Sanju George, sanju.george@bsmhft.nhs.uk
Summary
Dopaminergic agents are commonly used and effective treatments for restless legs syndrome (RLS), a disabling sensorimotor disorder.
Less known are some of the potentially disabling side effects of these treatments, particularly iatrogenic gambling addiction, as is described
here. Here the authors present a 62-year-old man, with a 20–year history of RLS, who developed gambling addiction while on dopaminergic
treatment. He was not forewarned of this side effect, nor was he ever screened for gambling behaviours prior to or during treatment. Eight
months after discontinuation of dopaminergic treatment and after 10 sessions of cognitive–behavioural therapy for gambling addiction, his
gambling behaviours have partially resolved. To our knowledge, this is the fi rst ever fi rst person account of this condition. To prevent the
devastating consequences of gambling addiction or to minimise its impact by early intervention, the authors call for clinicians involved in
treatment of RLS to follow these simple measures: screen patients for gambling behaviours prior to the onset and during dopaminergic
treatment; forewarn patients of this potential side effect; and if patients screen positive, refer them to specialist gambling treatment services,
in addition to making necessary changes to their medication regime.
BMJ Case Reports 2011; doi:10.1136/bcr.07.2011.4459
2 of 3
good. It was when I retired 2 years ago that I started gam-
bling. It started with minor stuff, like the bets you could
make in the daily papers – I started betting for no money.
But very soon, I was going to the bookies, round the cor-
ner from where I lived. I would bet on horses, football
matches and also play blackjack and slot machines. Before
I realised, it escalated from once or twice a week to an eve-
ryday pastime. Actually, it became more than a pastime.
And from spending a couple of pounds a week, I had got
to spending hundreds of pounds everyday: I was hooked.
I had to do it whether I had the money or not. I would
lie, borrow or steal from home. I would ask anyone and
everyone. Because I knew I could win and then could pay
it all back. I even started to gamble online, so no one had
to know and I did not even have to get out of the house.
In those 2 to 3 mad years, I lost over £50,000. Apart from
the money side of things, I lost the respect of my family
as well: my kids hated me and my wife blamed me for it.
I lost my ambition in life, apart from the need to gamble. I
had no time for anything or anyone else.
All this time, I was not associating my gambling with
the medication. How was I to know? One time, at my
sixth monthly check up with my specialist, I told him and
he immediately switched my medication. He also referred
me to the gambling clinic. And then over the next few
months I stopped gambling, or nearly stopped. I am still
frightened because the cravings are still there. Say, every
time I walk past a betting shop, if I have money in my
pocket, I’m scared, or when I get an e-mail offering a £5
free bet. I have had a few lapses in the past few months.
The way I control my gambling these days is by control-
ling my lifestyle; having other things to do. I go for walks,
swim and read a lot. I have got my ambition back and I’m
me again. My family is beginning to trust me again. My
advice to others would be – do not ever get into a betting
shop if you are on this medication. And to doctors – please
forewarn your patients about this side effect so it can be
nipped in the bud. And to fellow patients- certainly, do not
blame yourself, and get help as soon as you can’.
TREATMENT
The patient received 10 sessions of individual cognitive–
behavioural therapy for his gambling addiction, between
September 2010 and March 2011. Key issues discussed in
these sessions were: the role of behavioural conditioning
in gambling and triggers for the occasional lapses (seemed
to mostly involve complacency with regard to both carry-
ing reasonably large amounts of cash and a lack of fore-
sight when entering into high-risk situations). Discussions
also encompassed the patient’s lifestyle and adaptation to
retirement. Finally, the need for roles in order to provide a
sense of purpose and impose some structure on his spare
time was also discussed.
OUTCOME AND FOLLOW-UP
Details of the patient’s treatment aspects are covered in
other sections. In summary, the patient has, since com-
pletion of his 1:1 cognitive–behavioural therapy in March
2011 been completely abstinent from gambling. He still
reports occasional cravings, especially triggered by high-
risk situations such as walking past betting shops and
getting e-mail reminders from online betting schemes.
He is highly motivated to continue total abstinence from
gambling. He spends more time with his family and keeps
himself busy by pursuing other recreational activities.
DISCUSSION
The subject of dopaminergic treatment – induced gam-
bling addiction in patients with RLS had not been suffi -
ciently explored until recently. But encouragingly, over the
past few years researchers have attempted to understand
this area better. In perhaps one of the earliest accounts
Driver–Dunckley et al
9 studied 77 patients with idiopathic
RLS who were on one or more dopaminergic medica-
tions, for medication-induced gambling behaviours and
other compulsions. They found that 6% of their sample
had increased urges to gamble and spent increased time
gambling, specifi cally after the initiation of dopaminergic
medication. In a similar and more recent study, Dang et al
10
found the prevalence of impulse control disorders (ICDs)
in this cohort of patients to be 2.7%; these ICDs included
gambling addiction, kleptomania, compulsive shopping
and hypersexuality. They failed to establish a linear rela-
tionship between duration of dopaminergic treatment and
risk of onset of ICDs, but found that some of these iatro-
genic symptoms persisted beyond cessation of dopaminer-
gic treatment. This combined with the multiple fi nancial,
forensic, social and marital implications of these behav-
iours they found in this study made them call for ‘careful
consideration by clinicians of the emergence of ICDs and
discussion with patients.
In perhaps the most comprehensive review to date, of
all cases published, of patients with RLS who developed
gambling addiction while on dopaminergic therapy, d’Orsi
et al
11 identifi ed 15 cases. Key features found in this review
included the following: average age of onset was 59.8 (range
was 27 to 77), gender distribution – male: female was 7:8,
they were all on dopaminergic monotherapy, they had all
been on treatment for several months, some also experi-
enced other compulsive behaviours, none had a history of
gambling addiction but four were recreational gamblers in
the past, and gambling addiction ‘improved-resolved’ in all
patients upon cessation of dopaminergic treatment.
In light of the above published evidence, the patient’s
case described above seems not uncommon and fi ts with
previous reports. The patient had suffered from RLS since
early childhood and he had a family history of RLS. He
commenced dopaminergic treatment at the age of 40,
with sinemet and cabergoline. His symptoms of RLS were
reasonably well-controlled initially but as he developed
an augmentation phenomenon, he was switched from
cabergoline to ropinirole. On this medication, although
his symptoms of RLS improved, he developed a gambling
problem; he had had no history of such a problem. As soon
as this was identifi ed, he was switched to rotigotine but
his addiction to gambling persisted. It was then that his
medication was changed over to gabapentin and he was
also referred to the gambling clinic. He received 10 ses-
sions of cognitive–behavioural therapy for his gambling
addiction. Six months on, he is no longer addicted to gam-
bling but he has had a few lapses. His symptoms of RLS
are better controlled but he still struggles to get a refreshing
night’s sleep.
In our view what makes this case unusual from previ-
ous ones and hence all the more relevant to the clinician
are the following. First, the patient was never forewarned
BMJ Case Reports 2011; doi:10.1136/bcr.07.2011.4459 3 of 3
about this potential side effect (i.e. gambling addiction)
any time before, nor was he ever screened for gambling
behaviours during his dopaminergic treatment. Second,
it was not until well over 18 years of dopaminergic treat-
ment that he developed gambling addiction. Third, while
it would appear that the patient’s gambling is in remis-
sion 6 months after cessation of dopaminergic treatment,
he still continues to have cravings and occasional lapses
into gambling. Hence we call for clinicians involved in
treatment of RLS to follow these simple measures: screen
patients for gambling behaviours prior to the onset and
during dopaminergic treatment; forewarn patients of this
potential side effect; and if patients screen positive, refer
them to specialist gambling treatment services, in addition
to making necessary changes to their medication regime;
consider collaborative working between neurologists and
addiction specialists in treating these patients.
In conclusion, we hope this patient’s story has suc-
ceeded in raising clinicians’ awareness of this condition.
We end with a call to forewarn patients of this side effect
(i.e. iatrogenic gambling addiction) of dopaminergic medi-
cations, and stress the importance of regularly screening
patients for the development of gambling behaviours.
Learning points
Iatrogenic gambling addiction is a less known side
effect of dopaminergic agents, commonly used
treatments for RLS.
But very often this side effect goes unrecognised and
hence unaddressed.
We call for clinicians to forewarn patients of this
potential side effect and to screen patients for
gambling behaviours prior to the onset and during
dopaminergic treatment.
If patients screen positive, refer them to specialist
gambling treatment services, in addition to making
necessary changes to their dopaminergic medication
regime.
Acknowledgements We thank the patient for agreeing to share his story.
Competing interests None.
Patient consent Obtained.
REFERENCES
1 . Högl B, Kiechl S, Willeit J, et al . Restless legs syndrome: a community-based
study of prevalence, severity, and risk factors. Neurology 2005 ; 64 : 1920 – 4 .
2 . Allen RP, Picchietti D, Hening WA, et al . Restless legs syndrome: diagnostic
criteria, special considerations, and epidemiology. A report from the restless
legs syndrome diagnosis and epidemiology workshop at the National Institutes
of Health. Sleep Med 2003 ; 4 : 101 – 19 .
3 . Gamaldo CE, Earley CJ . Restless legs syndrome: a clinical update. Chest
2006 ; 130 : 1596 – 604 .
4 . Pourcher E, Rémillard S, Cohen H . Compulsive habits in restless
legs syndrome patients under dopaminergic treatment. J Neurol Sci
2010 ; 290 : 52 – 6 .
5 . Quickfall J, Suchowersky O . Pathological gambling associated with
dopamine agonist use in restless legs syndrome. Parkinsonism Relat Disord
2007 ; 13 : 535 – 6 .
6 . Tippmann-Peikert M, Park JG, Boeve BF, et al . Pathologic gambling in
patients with restless legs syndrome treated with dopaminergic agonists.
Neurology 2007 ; 68 : 301 – 3 .
7 . Voon V, Potenza MN, Thomsen T . Medication-related impulse control and
repetitive behaviors in Parkinson’s disease. Curr Opin Neurol 2007 ; 20 : 484 – 92 .
8 . Barns Neurauter MP, Rickards H, Cavanna AE . The prevalence and clinical
characteristics of pathological gambling in Parkinson’s disease: an evidence-
based review. Funct Neurol 2010 ; 25 : 9 – 13 .
9 . Driver-Dunckley ED, Noble BN, Hentz JG, et al . Gambling and increased
sexual desire with dopaminergic medications in restless legs syndrome. Clin
Neuropharmacol 2007 ; 30 : 249 – 55 .
10. Dang D, Cunnington D, Swieca J . The emergence of devastating impulse
control disorders during dopamine agonist therapy of the restless legs
syndrome. Clin Neuropharmacol 2011 ; 34 : 66 – 70 .
11. d’Orsi G, Demaio V, Specchio LM . Pathological gambling plus hypersexuality
in restless legs syndrome: a new case. Neurol Sci 2011 ; 32 : 707 – 9 .
This pdf has been created automatically from the fi nal edited text and images.
Copyright 2011 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit
http://group.bmj.com/group/rights-licensing/permissions.
BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.
Please cite this article as follows (you will need to access the article online to obtain the date of publication).
Jones HB, George S. ‘You never told me I would turn into a gambler’: a fi rst person account of dopamine agonist – induced gambling addiction in a patient with
restless legs syndrome. BMJ Case Reports 2011;10.1136/bcr.07.2011.4459, date of publication
Become a Fellow of BMJ Case Reports today and you can:
Submit as many cases as you like
Enjoy fast sympathetic peer review and rapid publication of accepted articles
Access all the published articles
Re-use any of the published material for personal use and teaching without further permission
For information on Institutional Fellowships contact consortiasales@bmjgroup.com
Visit casereports.bmj.com for more articles like this and to become a Fellow
... These 24 articles provided case reports of DA-related serious adverse mental disorder reactions experienced by 76 patients with RLS. [5][6][7]30,[52][53][54][64][65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80] Findings from these 24 articles can be found in Table 4. Among these 24 articles, we identified the following DA-induced serious adverse mental disorder reactions:  3 articles reporting 4 cases of DAWS, 52-54 ...
... article reporting 1 case of inadvertent overdose, 72  1 article reporting 1 case of paraphilia,78 15 articles reporting 66 cases of ICDs.[5][6][7][66][67][68][69][70][71]73,[75][76][77]79,80 ...
... These 24 articles provided case reports of DA-related serious adverse mental disorder reactions experienced by 76 patients with RLS. [5][6][7]30,[52][53][54][64][65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80] Findings from these 24 articles can be found in Table 4. Among these 24 articles, we identified the following DA-induced serious adverse mental disorder reactions: CARE AMONG PATIENTS NEWLY-DIAGNOSED WITH PRIMARY RESTLESS LEGS SYNDROME WITH AND WITHOUT PRIOR MENTAL DISORDERS: A LARGE-SCALE, MATCHED COHORT, RETROSPECTIVE CLAIMS ANALYSIS As previously noted, the increased risk for adverse mental disorder events among patients receiving DAs for PD is well documented. ...
... Some disorders that are classified in other nosographic categories (binge eating disorder in ''Feeding and Eating Disorders'' or gambling disorder in ''Substance-Related and Addictive Disorders'') are considered in the literature in this field as ICDs due to their clinical proximity or evolutions in classifications. Similar adverse drug reactions have also been reported in RLS [14][15][16][17][18][19][20][21][22][23] and prolactinoma patients [24,25], thus implying that nigrostriatal denervation is not a prerequisite for the development of ICD. However, only a minority of individuals with from PD, RLS, or prolactinoma develop ICDs. ...
Article
Full-text available
Impulse control disorders (ICDs) are a well-known adverse effect of dopamine agonists (DAAs). This critical review aims to summarize data on the prevalence and factors associated with the development of an ICD simultaneous to DAA use. A search of two electronic databases was completed from inception to July 2017. The search terms were medical subject headings (MeSH) terms including “dopamine agonists” AND “disruptive disorders”, “impulse control disorders”, or “conduct disorders”. Articles had to fulfill the following criteria to be included: (i) the target problem was an ICD; (ii) the medication was a dopaminergic drug; and (iii) the article was an original article. Of the potential 584 articles, 90 met the criteria for inclusion. DAAs were used in Parkinson’s disease (PD), restless legs syndrome (RLS) or prolactinoma. The prevalence of ICDs ranged from 2.6 to 34.8% in PD patients, reaching higher rates in specific PD populations; a lower prevalence was found in RLS patients. We found only two studies about prolactinoma. The most robust findings relative to the factors associated with the development of an ICD included the type of DAA, the dosage, male gender, a younger age, a history of psychiatric symptoms, an earlier onset of disease, a longer disease duration, and motor complications in PD. This review suggests that DAA use is associated with an increased risk in the occurrence of an ICD, under the combined influence of various factors. Guidelines to help prevent and to treat ICDs when required do exist, although further studies are required to better identify patients with a predisposition.
Article
Full-text available
Background Understanding and treating the harm caused by gambling is a growing international psychiatric and public health challenge. Treatment of gambling harm may involve psychological and pharmacological intervention, in conjunction with peer support. This scoping review was conducted to identify, for the first time, the characteristics and extent of United Kingdom (UK) based gambling treatment research. We reviewed studies conducted among people seeking treatment for disordered or harmful gambling in the UK, the settings, research designs, and outcome measures used, and to identify any treatment research gaps. Methods Systematic searches of PsycInfo, PsycArticles, Scopus, PubMed, and Web of Science databases were carried out for gambling treatment research or evaluation studies conducted in the UK. Studies were included if they evaluated the effectiveness of an intervention or treatment designed to improve symptoms of harmful or problematic gambling, reported outcomes of interventions on treatment adherence, gambling symptoms, or behaviours using standardised measures, were conducted in the UK, and were published since 2000. Results Eight studies met the inclusion criteria. Four were retrospective chart reviews, two were single-participant case reports, one described a retrospective case series, and one employed a cross-sectional design. None used an experimental design. Conclusion The limited number of studies included in this review highlights a relative paucity of gambling treatment research conducted in UK settings. Further work should seek to identify potential barriers and obstacles to conducting gambling treatment research in the UK.
Article
Full-text available
Restless legs syndrome (RLS) is a sensorimotor neurological disorder characterized by an urge to move the limbs with a circadian pattern (occurring in the evening/at night), more prominent at rest, and relieved with movements. RLS is one of the most prevalent sleep disorders, occurring in 5-10% of the European population. Thomas Willis first described RLS clinical cases already in the 17th century, and Karl-Axel Ekbom described the disease as a modern clinical entity in the 20th century. Despite variable severity, RLS can markedly affect sleep (partly through the presence of periodic legs movements) and quality of life, with a relevant socio-economic impact. Thus, its recognition and treatment are essential. However, screening methods present limitations and should be improved. Moreover, available RLS treatment options albeit providing sustained relief to many patients are limited in number. Additionally, տհե development of augmentation with dopamine agonists represents a major treatment problem. A better understanding of RLS pathomechanisms can bring to light novel treatment possibilities. With emerging new avenues of research in pharmacology, imaging, genetics, and animal models of RLS, this is an interesting and constantly growing field of research. This review will update the reader on the current state of RLS clinical practice and research, with a special focus on the contribution of European researchers.
Chapter
The Side Effects of Drugs Annuals form a series of volumes in which the adverse effects of drugs and adverse reactions to them are surveyed. The series supplements the contents of Meyler's Side Effects of Drugs: the International Encyclopedia of Adverse Drug Reactions and Interactions. This review of the 2011 publications on drugs that affect autonomic functions or the extrapyramidal system covers drugs that stimulate both alpha- and beta-adrenoceptors (adrenaline, noradrenaline, Ephedra and ephedrine, and pseudoephedrine), drugs that predominantly stimulate α1-adrenoceptors (phenylephrine), drugs that stimulate β1-adrenoceptors (dobutamine), drugs that stimulate β2-adrenoceptors (ritodrine), drugs that stimulate dopamine receptors (dopamine and the dopamine receptor agonist cabergoline), entacapone, and anticholinergic drugs, including orphenadrine. It also includes two special reviews on the dopamine receptor agonists rotigotine and piribedil. Recurrent features include reports of takotsubo cardiomyopathy and compulsive behavior associated with dopamine receptor agonists. There have also been many comparative studies, including noradrenaline versus dopamine and dopamine versus dobutamine to restore blood pressure.
Article
Full-text available
Since the introduction of levodopa therapy and dopaminergic replacement therapy to abate symptoms of idiopathic Parkinson's disease, repetitive compulsive behaviors have been reported and are now considered to be drug-related response complications. As dopamine (DA) agonists are the licensed treatment in Restless Legs Syndrome (RLS), a survey was conducted to determine the extent to which patients with RLS present compulsive behaviors. The aim of this study was to investigate the relationship between DA agonists and the occurrence of motor or behavioral compulsions, stress, depression, and sleep disturbance in RLS patients. A questionnaire was mailed three times, at four-month intervals over a period of 8 months to all patients of the Quebec Memory and Motor Skills Disorders Clinic diagnosed with RLS. In addition to recording all medication information for RLS treatment, patients were assessed on the International Restless Legs Syndrome Study Group Rating Scale (IRLS), the Beck Depression Inventory-II (BDI-II), the Sleep Scale from the Medical Outcomes Study (MOS) and on a visual analog scale for current level of stress. A section pertaining to hobby, mania, and compulsion was also included. Analyses are based on 97 out of 151 patients (64.2%) with RLS who returned the three questionnaires. Twelve patients (12.4%) on stable DA agonist therapy (average dose 0.52+/-0.59 mg Pramipexole equivalent) developed a new compulsive behavioral repertoire. Eating (3 women, 1 man), buying food or clothes (2 women, 1 man), trichotillomania (1 woman, 1 man), and gambling (1man) were among the compulsions developed under DA treatment. In addition, two women presented new tic-like phenomena. In contrast to the RLS patients without compulsive behaviors (53 treated with DA agonist; 32 untreated), those with compulsive habits reported experiencing more stress, depression and sleep problems. Patients with RLS with mood and stress states may be at greater risk of developing compulsive behaviors while receiving standard dosage DA agonist treatment. These behaviors are clearly linked to short-term satisfaction and underline the role of dopaminergic mesolimbic stimulation in the reinforcement process of rewarding behavioral sequences.
Article
Emerging clinical data indicate that dopaminergic agonists used to treat restless legs syndrome may be associated with dopamine dysregulation syndrome, particularly pathological gambling. We report a new case with pathological gambling plus hypersexuality and impotence in an old patient treated with a small dose (0.18 mg daily at bedtime) of pramipexole for restless legs syndrome for 5 months. The time relationship and the resolution upon discontinuation of dopaminergic agonists suggest a causative association. Our new case confirms that restless legs syndrome patients should be cautioned about potential dopamine dysregulation syndrome coinciding with dopaminergic agonists, as it can be reversed by drug withdrawal.
Article
The Restless Legs Syndrome is a common sensorimotor disorder, typically amenable to treatment with dopamine agonist therapy. Dopamine agonists have been associated with emergent impulse control disorders (ICDs) when used in patients with Parkinson disease, and ICDs have now been reported in individuals with RLS on dopamine agonist therapy. Our aim was to characterize cases of emergent ICDs in Australian patients with focus on the dopamine agonists implicated and the social significance of ICDs. A series of RLS patients on dopamine agonist therapy were identified with ICDs over a 2-year period. Additional cases of ICDs were found using a mailout questionnaire designed to capture those with high impulsivity. These patients were assessed using the Barratt Impulsiveness Scale, Version 11, and a modified Minnesota Impulse Disorders Interview. Case records and medication schedules were evaluated. Twelve cases of patients with de novo ICDs were found with a range of impulsive behaviors including pathological gambling, kleptomania, compulsive shopping, and hypersexuality. Criminality, suicidality, and marital discord also were featured. These occurred over a wide range of latencies and l-dopa exposures. This group of Australian RLS patients with ICDs display high levels of impulsivity and is the first to use the BIS-11 questionnaire in this setting. Impulse control disorders can occur over a wide range of dopamine agonist therapy types and dose exposures. Impulse control disorder tendencies may persist, despite withdrawal of dopamine agonists. The emergence of ICDs needs careful consideration in light of their potentially devastating financial, social, and marital consequences.
Article
Large prospective studies in the USA and Canada have estimated the prevalence of pathological gambling (PG) in the general population at 0.43% and 1% respectively. Studies using equivalent methodology in patients with Parkinson's disease (PD) have reported markedly higher prevalence rates. A total of 1032 patients with PD have been included in clinical studies in North America, Great Britain and Italy. Of these, 3.2% met diagnostic criteria for PG. The prevalence of PG was found to be higher in men than in women with PD, although the difference was not statistically significant. A younger age at onset of PD, increased novelty-seeking behaviour and a history of alcohol misuse have been found to be associated with PG in this population. Pathological gambling has been associated with dopamine agonist use, and the prevalence of the association has been found to be 5.7% in patients with PD. Although the literature suggests a high incidence of psychiatric co-morbidity, particularly depression and other impulse control disorders, this is yet to be confirmed by case-control studies.
Article
Restless legs syndrome is a common yet frequently undiagnosed sensorimotor disorder. In 1995, the International Restless Legs Syndrome Study Group developed standardized criteria for the diagnosis of restless legs syndrome. Since that time, additional scientific scrutiny and clinical experience have led to a better understanding of the condition. Modification of the criteria is now necessary to better reflect that increased body of knowledge, as well as to clarify slight confusion with the wording of the original criteria. The restless legs syndrome diagnostic criteria and epidemiology workshop at the National Institutes of Health. Members of the International Restless Legs Syndrome Study Group and authorities on epidemiology and the design of questionnaires and scales. To modify the current criteria for the diagnosis of restless legs syndrome, to develop new criteria for the diagnosis of restless legs syndrome in the cognitively impaired elderly and in children, to create standardized criteria for the identification of augmentation, and to establish consistent questions for use in epidemiology studies. The essential diagnostic criteria for restless legs syndrome were developed and approved by workshop participants and the executive committee of the International Restless Legs Syndrome Study Group. Criteria were also developed and approved for the additional aforementioned groups.
Article
To assess the prevalence and severity of restless legs syndrome (RLS) in the general community and to investigate its potential relationship with iron metabolism and other potential risk factors. This was a cross-sectional study of a sex- and age-stratified random sample of the general population (50 to 89 years; n = 701). The diagnosis of RLS was established by face-to-face interviews; severity was graded on the RLS severity scale. Each subject underwent a thorough clinical examination and extensive laboratory testing. The prevalence of RLS was 10.6% (14.2% in women, 6.6% in men); 33.8% of all patients with RLS had mild, 44.6% had moderate, and 21.6% had severe disease expression. None had been previously diagnosed or was on dopaminergic therapy. Free serum iron, transferrin, and ferritin concentrations were similar in subjects with and without RLS. However, soluble transferrin receptor (sTR) concentrations were different in subjects with and without RLS (1.48 vs 1.34 mg/L; p < 0.001). Female sex and high sTR independently predicted the risk of RLS. This large survey confirms the high prevalence, female preponderance, and underrecognition of restless legs syndrome in the general community. Although two-thirds of patients had moderate to severe disease, none was on current dopaminergic therapy.
Article
Restless legs syndrome (RLS) is a common and often disabling sensorimotor disorder. Epidemiologic studies suggest that RLS is an underrecognized and undertreated disorder affecting both children and adults. The diagnosis is based primarily on the following four essential criteria: (1) an urge to move, usually associated with paresthesias, (2) onset or exacerbation of symptoms at rest, (3) relief of symptoms with movement, and (4) symptoms manifesting in a circadian pattern. Supplemental workup including polysomnography, iron profile, and/or neuropathy screen can provide support for the diagnosis and aid in the treatment strategy. Behavioral techniques, dopaminergic agents, opiates, benzodiazepines, and antiepileptics all have potential value in treating this disorder. Dopaminergic agents continue to be the most effective RLS treatment. However, due to their potential long-term side effects, these agents should not be considered the sole treatment of choice. In the end, the therapeutic plan should be individualized to suit each patient's presentation and needs.
Article
Pathologic gambling is an impulse control disorder previously reported to complicate dopamine agonist therapy in patients with Parkinson disease. It has not been described in association with dopamine agonist therapy of other conditions. We report three patients treated in our sleep disorders center who developed pathologic gambling while receiving treatment with dopamine agonists for restless legs syndrome.
Article
Dopamine agonists (DA) have been associated with pathological gambling (PG) and other compulsive behaviors in Parkinson's disease (PD). Although these medications are used in other conditions, we are not aware of other reports of PG exclusive to treatment for idiopathic PD. We present a case of PG arising in the context of DA use for restless legs syndrome.
Article
A range of impulse control and repetitive behaviors presumed to be related to dopaminergic medications has been recognized in Parkinson's disease. These behaviors are linked by their incentive or reward-based and repetitive natures and overlap with addictions. The behaviors include pathological gambling, hypersexuality, compulsive shopping, and compulsive eating and are related to punding and compulsive medication use. In patients on dopamine agonists, these behaviors as a group are relatively common, can have potentially devastating psychosocial consequences and are commonly hidden. Recent studies have investigated prevalence rates and associated factors. The literature on these behaviors in Parkinson's disease, including definitions, epidemiology, pathophysiology and management, is reviewed. The relationship to medications, Parkinson's disease and individual susceptibility is examined. These behaviors can affect up to 14% of Parkinson's disease patients on dopamine agonists. Clinicians should warn patients prior to initiating dopamine agonists and enquire about these behaviors during follow up.